Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2011 Apr 15

PMID 21490127

Citations 29

Authors

Christian Kollmannsberger

Georg Bjarnason

Patrick Burnett

Patricia Creel

Mellar Davis

Nancy Dawson

Darren Feldman

Suzanne George

Jerome Hershman

Thomas Lechner

Amy Potter

Eric Raymond

Nathaniel Treister

Laura Wood

Shenhong Wu

Ronald Bukowski

Affiliations

Soon will be listed here.

Abstract

The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of care for good- and intermediate-risk metastatic renal cell carcinoma. Although generally associated with acceptable toxicity, sunitinib exhibits a novel and distinct toxicity profile that requires monitoring and management. Fatigue, diarrhea, anorexia, oral changes, hand-foot syndrome and other skin toxicity, thyroid dysfunction, myelotoxicity, and hypertension seem to be the most common and clinically relevant toxicities of sunitinib. Drug dosing and treatment duration are correlated with response to treatment and survival. Treatment recommendations for hypertension have been published but, currently, no standard guidelines exist for the management of noncardiovascular side effects. To discuss the optimal management of noncardiovascular side effects, an international, interdisciplinary panel of experts gathered in November 2009. Existing literature on incidence, severity, and underlying mechanisms of side effects as well as on potential treatment options were carefully reviewed and discussed. On the basis of these proceedings and the thorough review of the existing literature, recommendations were made for the monitoring, prevention, and treatment of the most common noncardiovascular side effects and are summarized in this review. The proactive assessment and consistent and timely management of sunitinib-related side effects are critical to ensure optimal treatment benefit by allowing appropriate drug dosing and prolonged treatment periods.

Citing Articles

Patients' Identification, Management and Prevention of Adverse Drug Reactions: A Cross-Sectional Survey of Patients with Severe Adverse Drug Reactions.

Srisuriyachanchai W, Cox A, Jarernsiripornkul N J Clin Med. 2024; 13(14).

PMID: 39064204 PMC: 11277768. DOI: 10.3390/jcm13144165.

Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy.

Villa A, Kuten-Shorrer M Int J Mol Sci. 2023; 24(9).

PMID: 37175898 PMC: 10179284. DOI: 10.3390/ijms24098188.

Kontsioti E, Maskell S, Bensalem A, Dutta B, Pirmohamed M Br J Clin Pharmacol. 2022; 88(9):4067-4079.

PMID: 35362214 PMC: 9545693. DOI: 10.1111/bcp.15341.

Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.

McGregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo A Cancer Treat Rev. 2022; 103:102333.

PMID: 35033866 PMC: 9590624. DOI: 10.1016/j.ctrv.2021.102333.

Supportive therapy and complementary medicine in renal cell carcinoma.

Johannsen M, Stoll C, Raida M, Van Oorschot B, Florcken A World J Urol. 2021; 40(10):2359-2371.

PMID: 34821959 DOI: 10.1007/s00345-021-03885-1.

References

Adams L, Shepard N, Caruso R, Norling M, Belansky H, Cunningham R . Putting evidence into practice: evidence-based interventions to prevent and manage anorexia. Clin J Oncol Nurs. 2009; 13(1):95-102. DOI: 10.1188/09.CJON.95-102. View

Rouffiac V, Bouquet C, Lassau N, Opolon P, Koscielny S, Peronneau P . Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol. 2004; 39(6):350-6. DOI: 10.1097/01.rli.0000124457.99229.bb. View

Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali P . A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007; 92(9):3531-4. DOI: 10.1210/jc.2007-0586. View

Gore M, Szczylik C, Porta C, Bracarda S, Bjarnason G, Oudard S . Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10(8):757-63. DOI: 10.1016/S1470-2045(09)70162-7. View

Sanchez-Barcelo E, Mediavilla M, Tan D, Reiter R . Clinical uses of melatonin: evaluation of human trials. Curr Med Chem. 2010; 17(19):2070-95. DOI: 10.2174/092986710791233689. View

Erber R, Thurnher A, Katsen A, Groth G, Kerger H, Hammes H . Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2003; 18(2):338-40. DOI: 10.1096/fj.03-0271fje. View

Mitchell S, Beck S, Hood L, Moore K, Tanner E . Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs. 2007; 11(1):99-113. DOI: 10.1188/07.CJON.99-113. View

Spence R, Heesch K, Brown W . Exercise and cancer rehabilitation: a systematic review. Cancer Treat Rev. 2009; 36(2):185-94. DOI: 10.1016/j.ctrv.2009.11.003. View

Beldner M, Jacobson M, Burges G, DeWaay D, Maize Jr J, Chaudhary U . Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist. 2007; 12(10):1178-82. DOI: 10.1634/theoncologist.12-10-1178. View

10.

Gramignano G, Lusso M, Madeddu C, Massa E, Serpe R, Deiana L . Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 2006; 22(2):136-45. DOI: 10.1016/j.nut.2005.06.003. View

11.

Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R . The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol. 2010; 30(5):704-10. DOI: 10.1016/j.urolonc.2010.07.015. View

12.

Alexandrescu D, Vaillant J, Dasanu C . Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol. 2006; 32(1):71-4. DOI: 10.1111/j.1365-2230.2006.02285.x. View

13.

Robert C, Soria J, Spatz A, Cesne A, Malka D, Pautier P . Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005; 6(7):491-500. DOI: 10.1016/S1470-2045(05)70243-6. View

14.

Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M . Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys. 2006; 64(5):1295-8. DOI: 10.1016/j.ijrobp.2005.12.004. View

15.

Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C . Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994; 42(11):1417-25. DOI: 10.1177/42.11.7523489. View

16.

Yavuzsen T, Davis M, Ranganathan V, Walsh D, Siemionow V, Kirkova J . Cancer-related fatigue: central or peripheral?. J Pain Symptom Manage. 2009; 38(4):587-96. DOI: 10.1016/j.jpainsymman.2008.12.003. View

17.

Hemesath T, Price E, Takemoto C, Badalian T, Fisher D . MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 1998; 391(6664):298-301. DOI: 10.1038/34681. View

18.

Motzer R, Hudes G, Curti B, Mcdermott D, Escudier B, Negrier S . Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007; 25(25):3958-64. DOI: 10.1200/JCO.2006.10.5916. View

19.

TAICHMAN N, Cruchley A, Fletcher L, Paleolog E, Abrams W, Booth V . Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis. Lab Invest. 1998; 78(7):869-75. View

20.

Motzer R, Basch E . Targeted drugs for metastatic renal cell carcinoma. Lancet. 2007; 370(9605):2071-3. DOI: 10.1016/S0140-6736(07)61874-1. View